Exelixis (EXEL) Stock Highlights

34.65 | +0.7%

2024-11-21 00:50:31

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Statistics

Range Today

34.26 34.81

Volume Today 1.68M

Range 1 Year

19.2 36.6

Volume 1 Year 520.93M

Range 3 Year

14.87 36.6

Volume 3 Year 1.76B

Range 10 Year

1.26 36.6

Volume 10 Year 8.38B

Highlights

Market Capitalization 10.35B (large)

Floating Shares 238.45M

Current Price 34.65

Price To Earnings 23.16

Price To Revenue 4.43

Price To Book 4.55

Earnings Per Share 1.55

Payout Ratio 0%

Performance

Latest +0.7%

1 Month +19.69%

3 Months +30.31%

6 Months +65.08%

1 Year +63.83%

3 Years +93.25%

5 Years +111.28%

10 Years +1950.3%

Benchmarks

Market Capitalization

29 / 368

Gross Profits

9 / 278

Total Revenue

12 / 300

Total Rank

121 / 368

Free Cashflow

256 / 352

Performance 5 years

69 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.